GlycoMimetics, Inc. (GLYC) DCF Valuation

Avaliação DCF GlyComimetics, Inc. (GLYC)

US | Healthcare | Biotechnology | NASDAQ
GlycoMimetics, Inc. (GLYC) DCF Valuation

Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas

Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria

Pré-Construídos Para Uso Rápido E Eficiente

Compatível com MAC/PC, totalmente desbloqueado

Não É Necessária Experiência; Fácil De Seguir

GlycoMimetics, Inc. (GLYC) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore GlyComimetics, Inc. (GLYC) Perspectivas financeiras com nossa calculadora DCF amigável! Digite suas suposições sobre crescimento, margens e despesas para calcular o valor intrínseco da Glycomimetics, Inc. (GLYC) e aprimore sua estratégia de investimento.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue 10.2 1.2 .1 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -88.59 -93.54 -86.65 -100 -92.2 -92.2 -92.2 -92.2 -92.2
EBITDA -51.2 -63.2 -47.2 -39.1 -40,039.4 .0 .0 .0 .0 .0
EBITDA, % -504.17 -5446.78 -62991.23 -391219.92 100 -60 -60 -60 -60 -60
Depreciation 1.0 1.0 1.0 .2 .0 .0 .0 .0 .0 .0
Depreciation, % 9.36 87.38 1377.59 1533.01 100 79.35 79.35 79.35 79.35 79.35
EBIT -52.2 -64.2 -48.2 -39.3 -40,039.4 .0 .0 .0 .0 .0
EBIT, % -513.53 -5534.16 -64368.81 -392752.93 100 -60 -60 -60 -60 -60
Total Cash 137.0 90.3 47.9 41.8 10,720.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .1 .4 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .1 .2 .1
Account Receivables, % 0.02114533 0.11612 192.21 1758.2 100
Inventories -1,237.1 -533.8 -.1 .0 .0 .0 .0 .0 .0 .0
Inventories, % -12172.51 -46017.7 -192.72 0 100 -40 -40 -40 -40 -40
Accounts Payable 2.1 2.1 1.0 .9 .3 .0 .0 .0 .0 .0
Accounts Payable, % 20.56 181.69 1294.88 8681.15 100 84.11 84.11 84.11 84.11 84.11
Capital Expenditure -.1 .0 -.1 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -0.67408 -1.29 -112.37 -213.94 100 -40.39 -40.39 -40.39 -40.39 -40.39
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -51.4 -63.9 -96.4 -39.3 -40,039.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1,188.6 -766.2 -630.4 -39.4 -40,039.9 -.2 .0 .0 .0 .0
WACC, % 5.43 5.47 5.49 5.49 5.49 5.47 5.47 5.47 5.47 5.47
PV UFCF
SUM PV UFCF -.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -11
Equity Value 10
Diluted Shares Outstanding, MM 64
Equity Value Per Share 0.16

What You Will Get

  • Real GlycoMimetics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on GlycoMimetics’ fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for GlycoMimetics, Inc. (GLYC).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to GLYC.
  • Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates for accurate modeling.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to GlycoMimetics, Inc. (GLYC).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  • 1. Access the Template: Download and open the Excel file containing GlycoMimetics, Inc.'s (GLYC) preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
  • 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
  • 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation possibilities.
  • 5. Present with Assurance: Deliver professional valuation insights to substantiate your strategic decisions.

Why Choose This Calculator?

  • User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
  • Customizable Inputs: Easily adjust parameters to suit your financial analysis.
  • Real-Time Feedback: Observe immediate updates to GlycoMimetics, Inc.'s (GLYC) valuation as you modify inputs.
  • Preloaded Data: Comes equipped with GlycoMimetics, Inc.'s (GLYC) latest financial information for swift evaluations.
  • Relied Upon by Experts: A go-to tool for investors and analysts seeking to make well-informed choices.

Who Should Use This Product?

  • Investors: Accurately assess GlycoMimetics, Inc.'s (GLYC) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to GlycoMimetics, Inc. (GLYC).
  • Consultants: Efficiently customize the template for valuation reports tailored to GlycoMimetics, Inc. (GLYC) clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech companies.
  • Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to GlycoMimetics, Inc. (GLYC).

What the Template Contains

  • Pre-Filled Data: Contains GlycoMimetics’ historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using custom inputs.
  • Key Financial Ratios: Evaluate GlycoMimetics’ profitability, efficiency, and leverage.
  • Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
  • Clear Dashboard: Visual representations and tables summarizing essential valuation results.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.